BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
Recs
TEVA is a "defensive" stock. not something that will boost your portfolio when the market goes bull.
people think its Generics, but 30% from TEVA's income is from ethics products - copaxone (for MS) and expose to generics competition. no biogenerics (FOB) in USA means no way to grow in the next 5 years after copaxone loses its patent.
"TEVA is a "defensive" stock. not something that will boost your portfolio when the market goes bull."
Maybe you should take a quick glance at the 10 year chart.
Copaxone is not exposed to generics competition; the FDA has ruled that its competitors must conduct their own clinical trials.